Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours
- 29 June 2004
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 151 (1) , 238-241
- https://doi.org/10.1111/j.1365-2133.2004.06026.x
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumorsAnnals of Oncology, 2003
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003
- Phase II Trial of Antiepidermal Growth Factor Receptor Antibody C225 in Patients with Advanced Renal Cell CarcinomaInvestigational New Drugs, 2003
- Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptorBritish Journal of Dermatology, 2002
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Chemoprevention of Breast Cancer: A Model for ChangeJournal of Clinical Oncology, 2002
- GefitinibDrugs, 2002
- Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225British Journal of Dermatology, 2001
- Acneiform DermatosesDermatology, 1998